Momenta Pharmaceuticals (MNTA) Stock Price, News & Analysis

Company Overview

Momenta Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery and development of novel biologic therapies for the treatment of rare immune-mediated diseases in the United States. Its novel therapeutic programs include M281, a fully-human anti-neonatal Fc receptor (FcRn), aglycosylated immunoglobulin G (IgG1), and monoclonal antibody to reduce circulating IgG antibodies by blocking endogenous IgG recycling via FcRn; M230, a recombinant trivalent human IgG1 Fc multimer containing three IgG Fc regions joined to maximize activity; and M254, a hyper-sialylated immunoglobulin to treat various inflammatory diseases, including idiopathic thrombocytopenic purpura and chronic inflammatory demyelinating polyneuropathy. The company's biosimilar programs comprise M923, a biosimilar of HUMIRA for the treatment of patients with rheumatoid arthritis, crohn's disease, ulcerative colitis, and psoriasis; and M710, a biosimilar of EYLEA for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema (DME), and diabetic retinopathy in patients with DME. Its complex generics programs include Enoxaparin sodium injection, a generic version of LOVENOX that is indicated for the prevention and treatment of deep vein thrombosis, as well as supports the treatment of acute coronary syndromes; GLATOPA, a generic version of once-daily COPAXONE for the treatment of patients with relapsing forms of multiple sclerosis; and GLATOPA, a generic version of three-times-weekly COPAXONE. The company has collaboration and license agreements with Sandoz AG, Mylan Ireland Limited, and CSL Behring Recombinant Facility AG. The company was formerly known as Mimeon, Inc. and changed its name to Momenta Pharmaceuticals, Inc. in September 2002. Momenta Pharmaceuticals, Inc. was founded in 2001 and is headquartered in Cambridge, Massachusetts.

Key Stats

• Today's Range: $52.48 to $52.48
• 50-Day Range: $52.26 to $52.49
• 52-Week Range: $12.21 to $52.53
• Volume: N/A
• Average Volume: 1.94 million shs
• Market Capitalization: $6.25 billion
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

MNTA Stock Analysis - Frequently Asked Questions

How were Momenta Pharmaceuticals' earnings last quarter?

Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) released its earnings results on Monday, August, 10th. The biotechnology company reported ($0.48) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.42) by $0.06. The biotechnology company had revenue of $6.61 million for the quarter, compared to analyst estimates of $5.84 million. Momenta Pharmaceuticals had a negative trailing twelve-month return on equity of 61.44% and a negative net margin of 757.61%.

What other stocks do shareholders of Momenta Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Momenta Pharmaceuticals investors own include NVIDIA (NVDA), Meta Platforms (META), Exelixis (EXEL), Gilead Sciences (GILD), Novavax (NVAX), Bristol-Myers Squibb (BMY) and Shopify (SHOP).

Company Calendar

• Last Earnings: 8/10/2020
• Today: 5/28/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biological Products, Except Diagnostic
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:MNTA
• CIK: 1235010
• Web: www.momentapharma.com
• Phone: 617-491-9700
• Fax: N/A
• Employees: 131
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($3.03)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$290.05 million
• Net Margins: -757.61%
• Pretax Margin: N/A
• Return on Equity: -61.44%
• Return on Assets: -45.28%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 6.38
• Quick Ratio: 6.38

Sales & Book Value

• Annual Sales: $23.87 million
• Price / Sales: 261.69
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $4.59 per share
• Price / Book: 11.43

Miscellaneous

• Outstanding Shares: 119,029,000
• Free Float: N/A
• Market Cap: $6.25 billion
• Optionable: Optionable
• Beta: 1.71